Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Resverlogix Corp. announces a warrant exercise incentive program designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company.
Indus Holdings, Inc. announced that it has changed the date of its previously announced earnings release and earnings call.
Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the closing of its previously announced offering.
“We are excited about entering into an agreement to acquire The Medicines Company as inclisiran is a potentially transformational medicine that reimagines the treatment of atherosclerotic heart disease and familial hypercholesterolemia,” said Vas Narasimhan, chief executive officer of Novartis.
The Board of Directors resolved on a rights issue of 75 MSEK, guaranteed to 80 percent, where the subscription period is ongoing
Philadelphia, PA – Oncoceutics, Inc. announced that new data will be presented on the efficacy and mechanism of action of imipridones ONC201 and ONC206 at the 24th Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona.
Crohn’s & Colitis Foundation’s IBD Ventures award supports development of Thetis’ novel first-in-class Resolvin oral therapy (TP-317) for treatment of ulcerative colitis and Crohn’s disease
A consortium jointly led by Astorg and Cinven announces that it has signed an agreement to acquire LGC, a global leader in the Life Sciences Tools sector.
Series A round lead investors NordicNinja and Industrifonden to support Combinostics as they scale to US and Asia
Vivoryon Therapeutics AG, will publish its third quarter financial results and a business update for the period ended September 30, 2019 on Thursday, November 28, 2019, in the form of an interim management report.